



RECEIVED

AUG 23 2002

TECH CENTER 1600/2900

SEQUENCE LISTING

<110> CREIGHTON UNIVERSITY

SMITH, Derek

SAHA, Shankar

ABEL, Peter

<120> PEPTIDE ANTAGONISTS OF CGRP-RECEPTOR SUPERFAMILY AND METHODS OF USE

<130> 180.00020102

<140> 09/813,345

<141> 2001-03-20

<150> 09/070,504

<151> 1998-04-30

<160> 23

C<sup>1</sup> <170> PatentIn version 3.0

<210> 1

<211> 30

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 1

Val Thr His Arg Leu Ala Gly Leu Leu Ser Arg Ser Gly Gly Met Val  
1 5 10 15

Lys Ser Asn Phe Val Pro Thr Asn Val Gly Ser Lys Ala Phe  
20 25 30

<210> 2

<211> 30

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 2

Val Thr His Arg Leu Ala Gly Leu Leu Ser Arg Ser Gly Gly Val Val  
1 5 10 15

Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser Lys Ala Phe  
20 25 30

<210> 3

<211> 37

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 3

Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
1 5 10 15

Ser Arg Ser Gly Gly Met Val Lys Ser Asn Phe Val Pro Thr Asn Val  
20 25 30

Gly Ser Lys Ala Phe  
35

<210> 4

<211> 37

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 4

Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
Page 2

1	5	10	15
Ser Arg Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val	20	25	30

Gly Ser Lys Ala Phe  
35

<210> 5

<211> 37

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 5

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu	1	5	10	15
---	---	---	----	----

Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val	20	25	30
---	----	----	----

Gly Ser Lys Ala Phe  
35

<210> 6

<211> 37

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 6

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu	1	5	10	15
---	---	---	----	----

Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val	20	25	30
---	----	----	----

Gly Ser Glu Ala Phe  
35

<210> 7

<211> 37

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 7

Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Asp Phe Leu  
1 5 10 15

Ser Arg Ser Gly Gly Val Gly Lys Asn Asn Phe Val Pro Thr Asn Val  
20 25 30

Gly Ser Lys Ala Phe  
35

<210> 8

<211> 37

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 8

Gly Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
1 5 10 15

Ser Arg Ser Gly Gly Met Val Lys Ser Asn Phe Val Pro Thr Asn Val  
20 25 30

Gly Ser Glu Ala Phe  
35

<210> 9

<211> 37

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 9

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
1 5 10 15

Ser Arg Ser Gly Gly Met Val Lys Ser Asn Phe Val Pro Thr Asp Val  
Page 4

C1  
Cont

	20	25	30
Gly Ser Glu Ala Phe			
	35		
<210>	10		
<211>	37		
<212>	PRT		
<213>	Artificial		
<220>			
<223>	peptide		
<400>	10		
Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu			
1	5	10	15
Ser Arg Ser Gly Gly Val Val Lys Ser Asn Phe Val Pro Thr Asn Val			
	20	25	30
Gly Ser Gln Ala Phe			
	35		
<210>	11		
<211>	37		
<212>	PRT		
<213>	Artificial		
<220>			
<223>	peptide		
<400>	11		
Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu			
1	5	10	15
Ser Arg Ser Gly Gly Val Val Lys Ser Asn Phe Val Pro Thr Asn Val			
	20	25	30
Gly Ser Glu Ala Phe			
	35		
<210>	12		
<211>	37		
<212>	PRT		
<213>	Artificial		

C1  
 Cont.

<220>

<223> peptide

<400> 12

Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Asp Phe Leu  
1 5 10 15  
Asn Arg Ser Gly Gly Met Gly Asn Ser Asn Phe Val Pro Thr Asn Val  
20 25 30  
Gly Ala Lys Ala Phe  
35

<210> 13

<211> 37

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 13

Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Asp Phe Leu  
1 5 10 15  
Ser Arg Ser Gly Gly Met Ala Lys Asn Asn Phe Val Pro Thr Asn Val  
20 25 30  
Gly Ser Lys Ala Phe  
35

<210> 14

<211> 52

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 14

Tyr Arg Gln Ser Met Asn Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys  
1 5 10 15  
Arg Phe Gly Thr Cys Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln  
20 25 30  
Phe Thr Asp Lys Asp Lys Asp Asn Val Ala Pro Arg Ser Lys Ile Ser



<213> Artificial

<220>

<223> peptide

<400> 17

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 18

<211> 30

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 18

Ala Thr Gln Arg Leu Ala Asn Phe Leu Val His Ser Ser Asn Asn Phe  
1 5 10 15

Gly Ala Ile Leu Ser Ser Thr Asn Val Gly Ser Asn Thr Tyr  
20 25 30

<210> 19

<211> 30

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 19

Ala Thr Gln Arg Leu Ala Asn Phe Leu Val Arg Ser Ser Asn Asn Leu  
1 5 10 15

Gly Pro Val Leu Pro Pro Thr Asn Val Gly Ser Asn Thr Tyr  
20 25 30

<210> 20

C1  
Cont



<211> 25

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 20

Val Leu Gly Lys Leu Ser Gln Glu Leu His Lys Leu Gln Thr Tyr Pro  
1 5 10 15

Arg Thr Asn Thr Gly Ser Asn Thr Tyr  
20 25

<210> 21

<211> 24

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 21

Leu Gly Arg Leu Ser Gln Glu Leu His Arg Leu Gln Thr Tyr Pro Arg  
1 5 10 15

Thr Asn Thr Gly Ser Asn Thr Tyr  
20

<210> 22

<211> 25

<212> PRT

<213> Artificial

<220>

<223> peptide

<400> 22

Ala Thr Gln Arg Leu Ala Asn Glu Leu Val Arg Leu Gln Thr Tyr Pro  
1 5 10 15

Arg Thr Asn Val Gly Ser Asn Thr Tyr  
20 25

<210> 23  
<211> 31  
<212> PRT  
<213> Artificial

<220>

<223> peptide

<400> 23

Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr Asp Lys Asp  
1 5 10 15  
Lys Asp Asn Val Ala Pro Arg Ser Lys Ile Ser Pro Gln Gly Tyr  
20 25 30

---